Japan Approves Insurance Coverage For Three Diagnostics
This article was originally published in PharmAsia News
Executive Summary
The Central Social Medical Insurance Agency (Chuikyo) April 21 approved insurance coverage for three diagnostic items. The council approved price listing for MESACUP anti-RNA polymerase III test for systemic scleroderma at ¥1,700, citing a high sensitivity in systemic scleroderma diagnosis and efficacy compared to current diagnostics. The test is developed by Medical and Biological Laboratories. In addition, two fatty acid binding protein diagnostics for acute myocardial infarction, developed separately by DS Pharma Biomedical and Biolinks, were priced at ¥1,500. Both diagnostics are able to obtain rapid results compared to current testing. (Click here for more - Japanese language)"Chuikyo Approves Medical Insurance For Three Diagnostics Including Systemic Scleroderma Testing" - Chemical Daily (4/14/2010)